Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.83 EUR Market Closed
Market Cap: 132.4m EUR

Heidelberg Pharma AG
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Heidelberg Pharma AG
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Heidelberg Pharma AG
XETRA:HPHA
Cash & Cash Equivalents
€29.4m
CAGR 3-Years
69%
CAGR 5-Years
24%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Cash & Cash Equivalents
€9.8B
CAGR 3-Years
79%
CAGR 5-Years
80%
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Cash & Cash Equivalents
€481.7m
CAGR 3-Years
-16%
CAGR 5-Years
73%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Cash & Cash Equivalents
€334.9m
CAGR 3-Years
23%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Cash & Cash Equivalents
€41.8m
CAGR 3-Years
-29%
CAGR 5-Years
-1%
CAGR 10-Years
-10%
Formycon AG
XETRA:FYB
Cash & Cash Equivalents
€41.8m
CAGR 3-Years
19%
CAGR 5-Years
14%
CAGR 10-Years
64%
No Stocks Found

Heidelberg Pharma AG
Glance View

Market Cap
132.4m EUR
Industry
Biotechnology

Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.

HPHA Intrinsic Value
2.28 EUR
Overvaluation 20%
Intrinsic Value
Price

See Also

What is Heidelberg Pharma AG's Cash & Cash Equivalents?
Cash & Cash Equivalents
29.4m EUR

Based on the financial report for Nov 30, 2024, Heidelberg Pharma AG's Cash & Cash Equivalents amounts to 29.4m EUR.

What is Heidelberg Pharma AG's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
24%

Over the last year, the Cash & Cash Equivalents growth was -32%. The average annual Cash & Cash Equivalents growth rates for Heidelberg Pharma AG have been 69% over the past three years , 24% over the past five years .

Back to Top